Brief: Volition Announces MARS Consortium Clinical Study Suggests Nu.Q H3.1 Concentrations Are Closely Associated With Sepsis And Organ Failure
12/06/2025 13:51
June 12 (Reuters) - VolitionRX Ltd VNRX.A: VOLITION ANNOUNCES MARS CONSORTIUM CLINICAL STUDY SUGGESTS NU.Q® H3.1. CONCENTRATIONS ARE CLOSELY ASSOCIATED WITH SEPSIS AND ORGAN FAILURE Source text: ID:nPnblsMN5a Further company coverage: VNRX.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on VolitionRX
See all newsBrief: Volitionrx -Files Preliminary Prospectus For 10,006,360 Shares Of Common Stock Offered By Selling Stockholder - SEC Filing
Brief: Volitionrx - Advances Nu.Q Nets Platform Towards Commercialization
Brief: VolitionRX Limited Announces First Quarter 2026 Financial Results
Brief: Volition Reports Breakthrough In Liquid Biopsy Achievement Of Over 99% Purity In Isolating Cancer Dna
Brief: Volition Announces First Ever Automated Nu.Q® Vet Cancer Test With Fujifilm Vet Systems